Effect of Silymarin in Metastatic Colorectal Cancer Patients

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

this work is aim to assess the antitumor effect of silymarin in patients with metastatic colorectal cancer receiving chemotherapy with or without target therapy (Bevacizumab).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Silymarin

Criteria

Inclusion Criteria:

• - Patients with histologically and/or radiologically confirmed diagnosis of metastatic colorectal carcinoma.

• Patients who received FOLFOX or XELOX as first line chemotherapy

• Both genders.

• Age ≥18 years old.

• Performance status 0-1 according to the Eastern Cooperative Oncology Group (ECOG).

• Patients with adequate hematologic parameters (white blood cell count

≥3000/mm3, granulocytes ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥ 8 gm/l).

• Patients with adequate renal functions (serum creatinine ≤1.5 mg/dL).

• Patients with adequate hepatic functions (bilirubin ≤1.5 mg/dL or albumin ≥3 g/dL).

Exclusion Criteria:

• - Patients with active liver diseases (chronic viral hepatitis, autoimmune hepatitis, alcoholic hepatitis, Wilson's disease, hemochromatosis, or cirrhosis).

• Patients with a history of other malignancy.

• Patients with brain metastasis.

• Patients with active infection.

• Patients with RAS wild type cancer.

• Patients on chronic use of corticosteroids.